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OBJECTIVES: To assess the correlation between the two QoL
instruments (SF-36, EQ-5D) and the scores of these instruments
to HAM-D scores in patients with major depressive disorder
(DSM-IV) during 6 week treatment period. Another aim was to
compare the efﬁcacy and safety of citalopram with S-citalopram
treatments in major depressive disorder. METHODS: Seventy-
four patients older than 18 years were recruited and randomly
assigned to receive citalopram (37) or S-citalopram (37) at 3
psychiatry units. Socio-demographic characteristics of the
patients and the HAM-D, SF-36 and EQ-5D scales were collected
before and at 2, 4, and 6 weeks after the treatment. At the end of
the study patient and physicians were asked to evaluate the
treatments with verbal score. RESULTS: All patients completed
the 6 week observation period. There was not any signiﬁcant
difference between both treatments for all measured parameters
at any time point. The mean HAM-D and EQ-5D utility score for
all patients at baseline were 23.5 (0.77) and 0.44 (0.035) and
improved to 5.0 (0.51) and 0.91 (0.015) at the end of the trial
(6. week), respectively. HAM-D were found to be well correlated
with EQ-5D (r = 0.77) and with the mental health measures of
SF-36; vitality (VT) (r = 0.79), social functioning (SF) (r = 0.70),
role emotional (RE) (r = 0.59) and mental health (MH) (r = 0.78)
subscales. The correlation between EQ-5D utility values and
SF-36 subscales indicated that mental health measures; VT
(r = 0.76), SF (r = 0.71), RE (r = 0.63) and MH (r = 0.76) have
better correlation coefﬁcient than physical health measures Cor-
relation between utility and VAS scores for EQ-5D was 0.79.
CONCLUSION: Both of the instruments are measuring the QoL
and are well correlated with the HAM-D scores. However since
EQ-5D has advantages (simple, easy and fast completion) it may
be introduced even in daily practice for assessment of the QoL in
major depression patients, efﬁciently.
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OBJECTIVES: To investigate the feasibility, and patient/
psychiatrist acceptability, of sending medication reminders and
well-being questions to patients receiving quetiapine via SMS-
messages. METHODS: This study was conducted by 7 Belgian
psychiatrists in outpatients receiving quetiapine according to
local label and considered capable of using their cellular-phone
and sending SMS-messaging. Twenty-seven outpatients (11 male;
16 female, mean age: 35.3 years) were followed for 8 to12 weeks
in this psychiatrist assessed, pilot-study. Patients received SMS-
messages twice daily to remind them to take their medication and
enquire about their well-being, fun messages could be received
optionally. Patients’ response was monitored by psychiatrists via
a website, and subsequently used to assess technical feasibility.
RESULTS: Patients responded to 77% of the SMS-messages (of
which 84% total response, 13% inaccurate response, 3% late
response). Twenty patients completed the study. The mean study
duration was 9.4 weeks. Response was higher in patients who
were supported in their disease by family/friends and who
showed good motivation. More than 50% of the patients rated
the degree of support offered by SMS as valuable (to a signiﬁcant/
reasonably extent). 71% appreciated the fun messages. The 2
major beneﬁts expressed by the patients were the feeling of being
cared for (n = 11/21) and the reminding to take their medication
(n = 7/21). Most of the psychiatrists felt that the system helped
improve compliance and relationship with the patient. Psychia-
trists felt the system was valuable to 19/22 patients, 16/24
patients remained compliant with the system and 16/22 patients
felt the frequency of SMS-messages was acceptable. There was a
strong correlation between patients giving positive well-being
responses and SMS-compliance (R Pearson = 0.72, p < 0.001).
CONCLUSION: The technology was favorably accepted and
performed well. The high levels of SMS-compliance and beneﬁts
expressed by patients and psychiatrists support a larger-scale
assessment of this possibility for assistance to health care
providers and patients.
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OBJECTIVES: Cholinesterase inhibitors and the NMDA-
receptor modulator memantine present the ﬁrst-line pharmaco-
therapy for Alzheimer’s disease, the most common type of
dementia. Effective and safe therapy requires drug administration
in a particular dose regimen, at speciﬁed times, and for a speciﬁc
period of time. The present study sets out to assess the adherence
of ambulatory Alzheimer patients to antidementia drugs by
means of electronic monitoring. METHODS: Adherence was
prospectively measured using MEMS (medication event monitor-
ing system). MEMS presents a medication container with a
microprocessor in the lid that records the date and time of every
opening. The study design comprises a one month run-in phase
followed by a main phase lasting six months. Percentage of days
with correctly administered doses of medication (daily adher-
ence) in the main phase, and number of patients with at least one
monthly (30 day period) daily adherence less than 80% were
deﬁned as main outcome measures. RESULTS: Adherence was
assessed in 16 patients (11 taking a once daily medication, 5 a
twice daily). Patients were prescribed one of the following drugs:
donepezil (n = 7), galantamine (n = 4), memantine (n = 4),
rivastigmine (n = 1). Daily adherence in main phase varied
from 48.3% to 99.4% (mean = 90.5%, median = 93.6%,
SD = 12.4%). A total of 5/16 patients (31%) had at least one
monthly adherence less than 80%. CONCLUSION: In general,
the study revealed a good medication taking behaviour with one
non-adherent day out of ten on average. Nevertheless, several
individuals exhibited major discrepancies that may potentially
endanger therapeutic goals. In a next step, another cohort of
patients and their caregivers will receive a pharmaceutical care
intervention including MEMS data feedback which might help to
optimize adherence.
Abstracts A303
